InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study in Patients with Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis

 InflaRx Reports Results of Vilobelimab in P- II IXPLORE Study in Patients with Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis

Shots:

  • The P-II IXPLORE study involves assessing vilobelimab (400/800mg, q2w) + SOC vs PBO + SOC in 19 patients with ANCA associated vasculitis or AAV in the US
  • The therapy is safe and well-tolerated in combination with SoC, clinical response & remission for each treatment group @16wks. was measured as 2EPs and showed 50% reduction in BVAS, patients in higher dose (800mg) showed BVAS (17.5mean / 16.5median), while 400mg dose showed (13.1 mean / 12.0 median) vs (13.8mean / 13.5median) with SOC group
  • The results further support the continued study of vilobelimab for the treatment of AAV. Part 1 & 2 of the P-II IXCHANGE trial are fully enrolled in the EU, results are expected in the end of 2021

Click here to­ read full press release/ article | Ref: InflaRx | Image: InflaRx

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post